# Onderbehandeling met antithrombotica verhoogt stroke- en sterftecijfers — AHA Scientific Statement

*geplaatst 2026-11-10 · Atriumfibrilleren · Circulation · doi 10.1161/CIR.0000000000001474 · https://hartvaat.nl/2026/11/03/onderbehandeling-met-antithrombotica-verhoogt-stroke-en-sterftecijfers-aha-scien/*

De American Heart Association schetst in een nieuwe Scientific Statement de ernstige gevolgen van onderbehandeling met antithrombotica bij patiënten met atriumfibrilleren, veneuze trombo-embolie of perifere arteriële ziekte. Uit de real-world data blijkt dat uitblijven, niet-adherentie of onderdosering van anticoagulantia en antiaggregantia leiden tot significante stijgingen in ischemische beroertes, recidiverende trombose en sterfte, met name bij kwetsbare populaties. Voor de klinische praktijk betekent dit dat gestructureerd antithrombotisch stewardship en interprofessionele samenwerking essentieel zijn om behandelgap's te dichten en de patiëntveiligheid te waarborgen.

## English: Impact of Undertreated Antithrombotic Therapy on Adverse Patient Outcomes: A Scientific Statement From the American Heart Association.

The American Heart Association highlights the substantial clinical and public health burden of antithrombotic undertreatment in patients with atrial fibrillation, venous thromboembolism, or peripheral artery disease. Real-world evidence consistently shows that omission, nonadherence, or underdosing significantly increases the risk of ischemic stroke, recurrent thrombosis, and mortality, with disparities often widening among patients facing social inequities. Clinicians across disciplines should prioritize structured antithrombotic stewardship programs to close these care gaps and optimize patient safety.

## Abstract (original, from the publication)

Antithrombotic therapy undertreatment includes omission, nonadherence, underdosing, and clinical circumstances that result in subtherapeutic antithrombotic levels. Antithrombotic undertreatment has profound implications for patient safety, public health, and healthcare costs. Due to deviation from evidence-based clinical practice, misperceptions of bleeding versus thrombotic risk, and inequities in healthcare access, many patients with atrial fibrillation, venous thromboembolism, or peripheral artery disease remain untreated or receive suboptimal anticoagulant dosing. Antithrombotic undertreatment has been shown to increase rates of ischemic stroke, systemic embolism, recurrent thrombosis, and mortality. Real-world data continue to highlight substantial gaps in care, which appear to be magnified in patients with inequity in social determinants of health. The emergence of antithrombotic stewardship, in concert with growing bodies of literature on antithrombotic agent underdosing, represents a transformative opportunity to address these gaps through structured, interprofessional, and evidence-based approaches. Through interdisciplinary collaboration, healthcare professionals are well positioned to enhance patient health and safety by recognizing and recommitting to reducing antithrombotic undertreatment.

Auteurs: Kelly Rudd, Youssef Bessada, Geoffrey D Barnes, Ulf G Bronas, Ashley N Budd, Taylor Goot, Natalie A Montanez, Toby Trujillo

---
Bron: Circulation, https://doi.org/10.1161/CIR.0000000000001474. Bijgewerkt 2026-11-03T02:18:56Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.